Paraguay to participate in Taiwanese Covid-19 vaccine clinical trial

The vaccine was developed using a traditional, protein subunit platform that is also used for other vaccines such as hepatitis B, the company representative explained.

RIO DE JANEIRO, BRAZIL - Paraguay will be part of phase 3 clinical trials of Medigen Vaccine Biologics Corporation of Taiwan's Covid-19 vaccine from next week, said the company's representative in the South American country Dr. Gabriela Horvat.

Some 2,000 doses of the MVC Covid-19 vaccine have been delivered to begin the trial, in which people over 18 years of age who have not been vaccinated against Covid-19 are eligible to participate, except pregnant or breastfeeding women.

The vaccine is administered in two doses, with a 29-day interval between them.

The vaccine was developed . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?